You are here

Pain Therapeutics Invites you to Join a Conference Call on Third Quarter 2018 Financial Results

Call to be held on Monday, October 29th at 4:30 p.m. Eastern Time

AUSTIN, Texas, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it will release third quarter 2018 financial results, and hold a conference call with a Q&A session, on Monday, October 29, 2018 at 4:30 p.m. Eastern Time.

The Company’s conference call can be accessed by dialing toll-free (877) 407-4018 (or 201 689-8471 for international callers).  A replay will be available toll-free at (844) 512-2921, (or 412 317-6671 for international callers), using the conference ID code 13684539.

To listen to the Company’s webcast, please go to and click on “News”, then “Event & Presentations” to register.  You may access at any time through Monday, November 5th, 2018, for a replay of the webcast for this conference call.

About the Company’s Neuroprotection Program
Our lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action for treating Alzheimer’s disease (“AD”).  We expect to initiate a Phase IIa study with PTI-125 in AD in Q4 2018.

The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, and benefits from several peer-reviewed research grant awards from the NIH.

We are also developing a blood-based test, called PTI-125Dx, to detect whether a person has Alzheimer’s disease, possibly years before any symptoms appear.  An early diagnosis of AD could optimize treatment options and empower physicians and patients to slow or halt the disease.

About Alzheimer's Disease
Alzheimer’s Disease (AD) is a progressive brain disorder that destroys memory and thinking skills. Eventually, a person with AD may be unable to carry out even the simplest tasks.  There is a profound and timely need to develop new drugs for Alzheimer’s.  Currently, there are no drug therapies to halt Alzheimer’s, much less reverse its course.

About Pain Therapeutics, Inc.
We develop proprietary drugs and diagnostics that offer significant improvements to patients and physicians. Our expertise consists of developing new products and guiding these through various regulatory and development pathways in preparation for their eventual commercialization.  The FDA has not yet established the safety or efficacy of our product candidates.

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Safe Harbor for forward-looking statements contained in the Act.  Examples of such statements include, but are not limited to, statements regarding the timing of clinical studies; and the potential benefits of the Company’s program in Alzheimer’s disease.  Such statements are based on management's current expectations, but actual results may differ materially due to various factors.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to our financial and operational ability to carry out development activities around Alzheimer’s disease.  For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.

For More Information Contact:

Eric Schoen
Chief Financial Officer
Pain Therapeutics, Inc. 
(512) 501-2450

Tuesday, October 23, 2018 - 07:30